Cognizant Reports Growth Projections of 4.6%-6.1%

Cognizant Technology Solutions (CTSH) has announced a projected growth range of 4.6%-6.1% and 3.5%-5.0% adjusted for constant currency. The company's financial health is underscored by its robust revenue growth, profitability metrics, and strong balance sheet. Cognizant's valuation metrics suggest the stock is fairly valued, with a P/E ratio of 15.41, P/S ratio of 1.83, and P/B ratio of 2.42. Analyst sentiment is moderately positive, with a target price of $87.9 and an RSI of 38.95, indicating potential upside and an oversold territory.

Cognizant Technology Solutions (CTSH) has released its second-quarter 2025 financial results, showcasing robust revenue growth and profitability. The company reported non-GAAP earnings per share (EPS) of $1.31, which exceeded the Zacks Consensus Estimate by 3.97% and marked a 12% year-over-year increase [1]. Revenue of $5.25 billion also beat the consensus mark by 1.01%, representing an 8.1% year-over-year increase and 7.2% growth at constant currency (cc) [1].

The quarter's performance was driven by the Belcan acquisition and strong organic growth, particularly in Health Sciences and Financial Services. The Belcan acquisition contributed approximately 400 basis points to the overall revenue growth [1]. On a trailing 12-month basis, bookings increased 6% year-over-year to $27.8 billion, with the second quarter including six large deals, including two mega deals valued at around $1 billion each [1].

Operating margins also improved, with the GAAP operating margin expanding 100 bps year-over-year to 15.6% and the non-GAAP operating margin (adjusted for NextGen charges) increasing 40 bps to 15.6% [1]. The company's strong financial health is further underscored by a total debt of $592 million as of June 30, 2025, and cash and short-term investments of $1.80 billion [1].

For the third quarter of 2025, Cognizant expects revenues between $5.27 billion and $5.35 billion, indicating growth of 4.6%-6.1% and an increase of 3.5%-5% on a cc basis. For the full year 2025, revenues are expected to be in the range of $20.7-$21.1 billion, representing growth of 4.7-6.7% on a reported basis and 4%-6% on a cc basis [1]. The adjusted operating margin for 2025 is expected to be approximately 15.5% to 15.7%, and adjusted EPS for 2025 is expected to be between $5.08 and $5.22 [1].

Valuation metrics suggest the stock is fairly valued. CTSH's price-to-earnings (P/E) ratio is 15.41, price-to-sales (P/S) ratio is 1.83, and price-to-book (P/B) ratio is 2.42. Analyst sentiment is moderately positive, with a target price of $87.9 and a relative strength index (RSI) of 38.95, indicating potential upside and an oversold territory [1].

References:
[1] https://www.nasdaq.com/articles/cognizant-q2-earnings-beat-estimates-will-raised-view-aid-shares
[2] https://news.cognizant.com/2025-07-30-Cognizant-Reports-Second-Quarter-2025-Results